Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

ConclusionsUsing the 2015-ATA evidence-based guidelines for the management of DTC, meaning no131I administration in low-risk patients, a low activity in intermediate and even high risk patients, and a systematic use of rhTSH stimulation before131I therapy allowed us to reduce significantly the median administered131I activity, with a similar rate of complete therapeutic response.
Source: Thyroid Research - Category: Endocrinology Source Type: research